May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- New studies highlight opportunities to improve pediatric anesthesia safety, comfort
- Social and behavioral factors emerging as key predictors of recovery quality after surgery
- Hospitals being squeezed: Anesthesia workforce gaps, payer cuts threaten surgery access
- CDC layoffs cripple national injury and overdose tracking, leaving prevention efforts in doubt
- The Joint Commission makes nurse staffing a national performance goal for 2026
- Telehealth in limbo: Providers split on continuing Medicare services during shutdown
- States take aim at outpatient facility fees driving higher commercial health costs
- Slower acquisitions, mounting debt reshape Surgery Partners growth outlook
- ASCs surge as hospitals and investors chase outpatient growth
- Nearly half of US physicians now work for large systems: GAO links consolidation to higher costs
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement